Literature DB >> 23653392

Possible involvement of CD10 in the development of endometriosis due to its inhibitory effects on CD44-dependent cell adhesion.

Akira Iwase1, Tomomi Kotani, Maki Goto, Hiroharu Kobayashi, Sachiko Takikawa, Tatsuo Nakahara, Tomoko Nakamura, Mika Kondo, Yoshinari Nagatomo, Fumitaka Kikkawa.   

Abstract

A reduced response to progesterone in the eutopic endometrium with endometriosis and in endometriotic tissues is considered to be the underlying factor for endometriosis. CD10 is known to be expressed by endometrial and endometriotic stromal cells and may be induced by progestins, although the function of CD10 is not fully revealed in endometrial or endometriotic tissues. In the current study, the expression of CD10 was significantly increased by treatment of the cells with progesterone, 17β-estradiol, and dibutyryl cyclic adenosine monophosphate (cAMP) in the endometrial stromal cells. On the other hand, the expression of CD10 following treatment with progesterone, 17β-estradiol, and dibutyryl cAMP was not significantly increased in endometriotic stromal cells. The adhesion assay for endometrial and endometriotic stromal cells to hyaluronan using 5- or 6-(N-succinimidyloxycarbonyl)-fluorescein 3', 6'-diacetate-labeled cells demonstrated that the CD44-dependent adhesion of stromal cells was inhibited by CD10. As far as the induction of CD10 is concerned, the effect of progesterone was different between endometrial stromal cells and endometriotic stromal cells. CD10 might be involved in the development of endometriosis due to its influence on CD44-dependent cell adhesion.

Entities:  

Keywords:  CD10; CD44; adhesion; endometriosis; stromal cells.

Mesh:

Substances:

Year:  2013        PMID: 23653392      PMCID: PMC3857763          DOI: 10.1177/1933719113488449

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  40 in total

Review 1.  Endometriosis.

Authors:  Linda C Giudice; Lee C Kao
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

2.  Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter.

Authors:  Rong Zheng; Ruoqian Shen; Oscar B Goodman; David M Nanus
Journal:  Mol Cell Endocrinol       Date:  2006-09-01       Impact factor: 4.102

3.  Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis.

Authors:  Richard O Burney; Said Talbi; Amy E Hamilton; Kim Chi Vo; Mette Nyegaard; Camran R Nezhat; Bruce A Lessey; Linda C Giudice
Journal:  Endocrinology       Date:  2007-05-17       Impact factor: 4.736

4.  Neutral endopeptidase expressed by decidualized stromal cells suppresses akt phosphorylation and deoxyribonucleic acid synthesis induced by endothelin-1 in human endometrium.

Authors:  Akira Iwase; Hisao Ando; Tetsuro Nagasaka; Daijiro Shibata; Toko Harata; Yuji Shimomura; Maki Goto; Fumitaka Kikkawa
Journal:  Endocrinology       Date:  2006-08-03       Impact factor: 4.736

5.  Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium.

Authors:  Soraya Labied; Takeshi Kajihara; Patricia A Madureira; Luca Fusi; Marius C Jones; Jenny M Higham; Rana Varshochi; Julia M Francis; Georgia Zoumpoulidou; Abdelkader Essafi; Silvia Fernandez de Mattos; Eric W-F Lam; Jan J Brosens
Journal:  Mol Endocrinol       Date:  2005-08-25

6.  Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.

Authors:  C N Papandreou; B Usmani; Y Geng; T Bogenrieder; R Freeman; S Wilk; C L Finstad; V E Reuter; C T Powell; D Scheinberg; C Magill; H I Scher; A P Albino; D M Nanus
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

7.  An assay for functional dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) inhibitors of human dendritic cell adhesion.

Authors:  Natasa Obermajer; Urban Svajger; Matjaz Jeras; Sara Sattin; Anna Bernardi; Marko Anderluh
Journal:  Anal Biochem       Date:  2010-07-25       Impact factor: 3.365

Review 8.  Novel therapeutic strategies for endometriosis: a pathophysiological perspective.

Authors:  Yutaka Osuga
Journal:  Gynecol Obstet Invest       Date:  2008-10-21       Impact factor: 2.031

9.  Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.

Authors:  Makoto Sumitomo; Akira Iwase; Rong Zheng; Daniel Navarro; David Kaminetzky; Ruoqian Shen; Maria-Magdalena Georgescu; David M Nanus
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

10.  Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2.

Authors:  S Yonemura; M Hirao; Y Doi; N Takahashi; T Kondo; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

View more
  4 in total

Review 1.  Drug delivery for the treatment of endometriosis and uterine fibroids.

Authors:  David R Friend
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

Review 2.  Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

Authors:  Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2021-01-25       Impact factor: 13.281

3.  MicroRNA‑16 inhibits endometrial stromal cell migration and invasion through suppression of the inhibitor of nuclear factor‑κB kinase subunit β/nuclear factor‑κB pathway.

Authors:  Xiaoping Wang; Rui Ren; Meili Shao; Jun Lan
Journal:  Int J Mol Med       Date:  2020-05-29       Impact factor: 4.101

4.  Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation.

Authors:  Meng-Dan Zhao; Jin-Lin Cheng; Jing-Jing Yan; Feng-Ying Chen; Jian-Zhong Sheng; Dong-Li Sun; Jian Chen; Jing Miao; Run-Ju Zhang; Cai-Hong Zheng; He-Feng Huang
Journal:  Int J Nanomedicine       Date:  2016-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.